Compare SLDB & WGO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SLDB | WGO |
|---|---|---|
| Founded | 2013 | 1958 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Homebuilding |
| Sector | Health Care | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 781.7M | 743.5M |
| IPO Year | 2017 | 1994 |
| Metric | SLDB | WGO |
|---|---|---|
| Price | $6.86 | $23.35 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 13 | 14 |
| Target Price | $18.62 | ★ $37.80 |
| AVG Volume (30 Days) | ★ 1.2M | 597.2K |
| Earning Date | 11-02-2026 | 10-21-2026 |
| Dividend Yield | N/A | ★ 5.84% |
| EPS Growth | 34.97 | ★ 106.82 |
| EPS | N/A | ★ 0.87 |
| Revenue | $8,094,000.00 | ★ $1,985,674,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $4.36 |
| P/E Ratio | ★ N/A | $28.33 |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $3.79 | $24.13 |
| 52 Week High | $11.45 | $50.16 |
| Indicator | SLDB | WGO |
|---|---|---|
| Relative Strength Index (RSI) | 29.65 | 23.92 |
| Support Level | $6.76 | N/A |
| Resistance Level | $7.26 | $30.90 |
| Average True Range (ATR) | 0.39 | 0.84 |
| MACD | -0.06 | -0.20 |
| Stochastic Oscillator | 9.05 | 0.00 |
Solid Biosciences Inc is a life sciences company focused on advancing a portfolio of current and future gene therapy candidates, including SGT-003 for the treatment of Duchenne muscular dystrophy, SGT-212 for the treatment of Friedreich's ataxia, SGT-501 for the treatment of catecholaminergic polymorphic ventricular tachycardia, SGT-601 for the treatment of TNNT2-mediated dilated cardiomyopathy, and additional assets for the treatment of genetic cardiac and neuromuscular diseases. The majority of its current programs are designed to treat these diseases with gene transfer products. The company operates in a single segment, developing treatments through gene therapy and other means for patients with neuromuscular and cardiac diseases.
Winnebago Industries manufactures Class A, B, and C motor homes along with towables, customized specialty vehicles, boats, and parts. Headquartered in Eden Prairie, Minnesota, Winnebago has been producing recreational vehicles since 1958. Revenue was $2.8 billion in fiscal 2025. Winnebago expanded into towables in 2010 with the acquisition of SunnyBrook and acquired Grand Design in 2016. Towables made up 84% of the firm's RV unit volume, up from 31% in fiscal 2016. The company's total fiscal 2025 RV unit volume was 36,911. Winnebago expanded into boating in 2018 with the purchase of Chris-Craft, bought premium motor home maker Newmar in 2019, and acquired Barletta pontoon boats in 2021. It also is developing electric and autonomous technology.